Effectiveness and Tolerance of the Hypericum Extract LI 160 in Comparison with Imipramine: Randomized Double-Blind Study with 135 Outpatients
In a double-blind comparative study, 135 depressed patients were treated in 20 centers. Inclusion diagnoses were typical depressions with single episode (296.2), several episodes (296.3), depressive neurosis (300.4), and adjustment disorder with depressed mood (309.0) in accordance with DSM-III-R. T...
Gespeichert in:
| Veröffentlicht in: | Journal of geriatric psychiatry and neurology 1994, Vol.7 (1_suppl), p.19-23 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 23 |
|---|---|
| container_issue | 1_suppl |
| container_start_page | 19 |
| container_title | Journal of geriatric psychiatry and neurology |
| container_volume | 7 |
| creator | Vorbach, E.-U. Hübner, W.-D. Arnoldt, K.-H. |
| description | In a double-blind comparative study, 135 depressed patients were treated in 20 centers. Inclusion diagnoses were typical depressions with single episode (296.2), several episodes (296.3), depressive neurosis (300.4), and adjustment disorder with depressed mood (309.0) in accordance with DSM-III-R. The dosage was 3 x 300 mg hypericum extract LI 160 or 3 x 25 mg imipramine daily. The treatment lasted for 6 weeks. Main assessment criteria were the Hamilton Depression Scale (HAMD), the Depression Scale according to von Zerssen (D-S) and the Clinical Global Impressions (CGI). In both treatment groups, a parallel reduction of the Hamilton score from 20.2 to 8.8 (LI 160, n = 67) or from 19.4 to 10.7 (imipramine, n = 68), and the transformed D-S point values from 39.6 to 27.2 (LI 160) and 39.0 to 29.2 (imipramine) were found. The analysis of CGI revealed comparable results in both treatment groups. Clinically relevant changes of the safety parameters were not found. In the LI 160 group fewer and milder side effects were found as compared to imipramine. |
| doi_str_mv | 10.1177/089198879400701s07 |
| format | Article |
| fullrecord | <record><control><sourceid>sage_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1177_089198879400701s07</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sage_id>10.1177_089198879400701s07</sage_id><sourcerecordid>10.1177_089198879400701s07</sourcerecordid><originalsourceid>FETCH-LOGICAL-c278t-546a60df78c8c2c33b476769c30623504bf09fa4a042837830ed44733e67242f3</originalsourceid><addsrcrecordid>eNp9kM1qGzEUhUVISNw0L1AI6AWmvvobabprXLcxGAKJux5kzVWj4PlB0qR13yHv3DEO3QSyuotzvnO4h5BPDD4zpvUcTMUqY3QlATSwBPqEzJhSvFAazCmZHQzFwXFBPqT0BACqMuKcnGujtAI-Iy9L79Hl8IwdpkRt19BNv8NoO4e09zQ_Ir3dDxiDG1u6_JOjdZmuV5SVQENHF3072BhS39HfIT_SVRuGaNvQ4Rd6P6X1bfiLDf3Wj9sdFje7MBU85LHZH-1MKHo35sHmgF1OH8mZt7uEV6_3kvz8vtwsbov13Y_V4uu6cFybXChZ2hIar40zjjshtlKXuqycgJILBXLrofJWWpDcCG0EYCOlFgJLzSX34pLwY66LfUoRfT3E0Nq4rxnUh2nrt9NO0PURGsZti81_5HXLSZ8f9WR_Yf3Uj7Gbfngv8R-Qg4G4</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Effectiveness and Tolerance of the Hypericum Extract LI 160 in Comparison with Imipramine: Randomized Double-Blind Study with 135 Outpatients</title><source>MEDLINE</source><source>SAGE Complete A-Z List</source><creator>Vorbach, E.-U. ; Hübner, W.-D. ; Arnoldt, K.-H.</creator><creatorcontrib>Vorbach, E.-U. ; Hübner, W.-D. ; Arnoldt, K.-H.</creatorcontrib><description>In a double-blind comparative study, 135 depressed patients were treated in 20 centers. Inclusion diagnoses were typical depressions with single episode (296.2), several episodes (296.3), depressive neurosis (300.4), and adjustment disorder with depressed mood (309.0) in accordance with DSM-III-R. The dosage was 3 x 300 mg hypericum extract LI 160 or 3 x 25 mg imipramine daily. The treatment lasted for 6 weeks. Main assessment criteria were the Hamilton Depression Scale (HAMD), the Depression Scale according to von Zerssen (D-S) and the Clinical Global Impressions (CGI). In both treatment groups, a parallel reduction of the Hamilton score from 20.2 to 8.8 (LI 160, n = 67) or from 19.4 to 10.7 (imipramine, n = 68), and the transformed D-S point values from 39.6 to 27.2 (LI 160) and 39.0 to 29.2 (imipramine) were found. The analysis of CGI revealed comparable results in both treatment groups. Clinically relevant changes of the safety parameters were not found. In the LI 160 group fewer and milder side effects were found as compared to imipramine.</description><identifier>ISSN: 0891-9887</identifier><identifier>EISSN: 1552-5708</identifier><identifier>DOI: 10.1177/089198879400701s07</identifier><identifier>PMID: 7857502</identifier><language>eng</language><publisher>Los Angeles, CA: SAGE Publications</publisher><subject>Adult ; Aged ; Antidepressive Agents - adverse effects ; Antidepressive Agents - therapeutic use ; Depression - diagnosis ; Depression - drug therapy ; Double-Blind Method ; Female ; Humans ; Hypericum ; Imipramine - adverse effects ; Imipramine - therapeutic use ; Male ; Middle Aged ; Perylene - adverse effects ; Perylene - analogs & derivatives ; Perylene - therapeutic use ; Plant Extracts - adverse effects ; Plant Extracts - therapeutic use ; Plants, Medicinal ; Psychometrics ; Quercetin - adverse effects ; Quercetin - analogs & derivatives ; Quercetin - therapeutic use ; Severity of Illness Index ; Xanthenes - adverse effects ; Xanthenes - therapeutic use</subject><ispartof>Journal of geriatric psychiatry and neurology, 1994, Vol.7 (1_suppl), p.19-23</ispartof><rights>1994 SAGE Publications.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c278t-546a60df78c8c2c33b476769c30623504bf09fa4a042837830ed44733e67242f3</citedby><cites>FETCH-LOGICAL-c278t-546a60df78c8c2c33b476769c30623504bf09fa4a042837830ed44733e67242f3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://journals.sagepub.com/doi/pdf/10.1177/089198879400701s07$$EPDF$$P50$$Gsage$$H</linktopdf><linktohtml>$$Uhttps://journals.sagepub.com/doi/10.1177/089198879400701s07$$EHTML$$P50$$Gsage$$H</linktohtml><link.rule.ids>314,777,781,4010,21800,27904,27905,27906,43602,43603</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/7857502$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Vorbach, E.-U.</creatorcontrib><creatorcontrib>Hübner, W.-D.</creatorcontrib><creatorcontrib>Arnoldt, K.-H.</creatorcontrib><title>Effectiveness and Tolerance of the Hypericum Extract LI 160 in Comparison with Imipramine: Randomized Double-Blind Study with 135 Outpatients</title><title>Journal of geriatric psychiatry and neurology</title><addtitle>J Geriatr Psychiatry Neurol</addtitle><description>In a double-blind comparative study, 135 depressed patients were treated in 20 centers. Inclusion diagnoses were typical depressions with single episode (296.2), several episodes (296.3), depressive neurosis (300.4), and adjustment disorder with depressed mood (309.0) in accordance with DSM-III-R. The dosage was 3 x 300 mg hypericum extract LI 160 or 3 x 25 mg imipramine daily. The treatment lasted for 6 weeks. Main assessment criteria were the Hamilton Depression Scale (HAMD), the Depression Scale according to von Zerssen (D-S) and the Clinical Global Impressions (CGI). In both treatment groups, a parallel reduction of the Hamilton score from 20.2 to 8.8 (LI 160, n = 67) or from 19.4 to 10.7 (imipramine, n = 68), and the transformed D-S point values from 39.6 to 27.2 (LI 160) and 39.0 to 29.2 (imipramine) were found. The analysis of CGI revealed comparable results in both treatment groups. Clinically relevant changes of the safety parameters were not found. In the LI 160 group fewer and milder side effects were found as compared to imipramine.</description><subject>Adult</subject><subject>Aged</subject><subject>Antidepressive Agents - adverse effects</subject><subject>Antidepressive Agents - therapeutic use</subject><subject>Depression - diagnosis</subject><subject>Depression - drug therapy</subject><subject>Double-Blind Method</subject><subject>Female</subject><subject>Humans</subject><subject>Hypericum</subject><subject>Imipramine - adverse effects</subject><subject>Imipramine - therapeutic use</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Perylene - adverse effects</subject><subject>Perylene - analogs & derivatives</subject><subject>Perylene - therapeutic use</subject><subject>Plant Extracts - adverse effects</subject><subject>Plant Extracts - therapeutic use</subject><subject>Plants, Medicinal</subject><subject>Psychometrics</subject><subject>Quercetin - adverse effects</subject><subject>Quercetin - analogs & derivatives</subject><subject>Quercetin - therapeutic use</subject><subject>Severity of Illness Index</subject><subject>Xanthenes - adverse effects</subject><subject>Xanthenes - therapeutic use</subject><issn>0891-9887</issn><issn>1552-5708</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1994</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kM1qGzEUhUVISNw0L1AI6AWmvvobabprXLcxGAKJux5kzVWj4PlB0qR13yHv3DEO3QSyuotzvnO4h5BPDD4zpvUcTMUqY3QlATSwBPqEzJhSvFAazCmZHQzFwXFBPqT0BACqMuKcnGujtAI-Iy9L79Hl8IwdpkRt19BNv8NoO4e09zQ_Ir3dDxiDG1u6_JOjdZmuV5SVQENHF3072BhS39HfIT_SVRuGaNvQ4Rd6P6X1bfiLDf3Wj9sdFje7MBU85LHZH-1MKHo35sHmgF1OH8mZt7uEV6_3kvz8vtwsbov13Y_V4uu6cFybXChZ2hIar40zjjshtlKXuqycgJILBXLrofJWWpDcCG0EYCOlFgJLzSX34pLwY66LfUoRfT3E0Nq4rxnUh2nrt9NO0PURGsZti81_5HXLSZ8f9WR_Yf3Uj7Gbfngv8R-Qg4G4</recordid><startdate>1994</startdate><enddate>1994</enddate><creator>Vorbach, E.-U.</creator><creator>Hübner, W.-D.</creator><creator>Arnoldt, K.-H.</creator><general>SAGE Publications</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>1994</creationdate><title>Effectiveness and Tolerance of the Hypericum Extract LI 160 in Comparison with Imipramine: Randomized Double-Blind Study with 135 Outpatients</title><author>Vorbach, E.-U. ; Hübner, W.-D. ; Arnoldt, K.-H.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c278t-546a60df78c8c2c33b476769c30623504bf09fa4a042837830ed44733e67242f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1994</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Antidepressive Agents - adverse effects</topic><topic>Antidepressive Agents - therapeutic use</topic><topic>Depression - diagnosis</topic><topic>Depression - drug therapy</topic><topic>Double-Blind Method</topic><topic>Female</topic><topic>Humans</topic><topic>Hypericum</topic><topic>Imipramine - adverse effects</topic><topic>Imipramine - therapeutic use</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Perylene - adverse effects</topic><topic>Perylene - analogs & derivatives</topic><topic>Perylene - therapeutic use</topic><topic>Plant Extracts - adverse effects</topic><topic>Plant Extracts - therapeutic use</topic><topic>Plants, Medicinal</topic><topic>Psychometrics</topic><topic>Quercetin - adverse effects</topic><topic>Quercetin - analogs & derivatives</topic><topic>Quercetin - therapeutic use</topic><topic>Severity of Illness Index</topic><topic>Xanthenes - adverse effects</topic><topic>Xanthenes - therapeutic use</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Vorbach, E.-U.</creatorcontrib><creatorcontrib>Hübner, W.-D.</creatorcontrib><creatorcontrib>Arnoldt, K.-H.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><jtitle>Journal of geriatric psychiatry and neurology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Vorbach, E.-U.</au><au>Hübner, W.-D.</au><au>Arnoldt, K.-H.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Effectiveness and Tolerance of the Hypericum Extract LI 160 in Comparison with Imipramine: Randomized Double-Blind Study with 135 Outpatients</atitle><jtitle>Journal of geriatric psychiatry and neurology</jtitle><addtitle>J Geriatr Psychiatry Neurol</addtitle><date>1994</date><risdate>1994</risdate><volume>7</volume><issue>1_suppl</issue><spage>19</spage><epage>23</epage><pages>19-23</pages><issn>0891-9887</issn><eissn>1552-5708</eissn><abstract>In a double-blind comparative study, 135 depressed patients were treated in 20 centers. Inclusion diagnoses were typical depressions with single episode (296.2), several episodes (296.3), depressive neurosis (300.4), and adjustment disorder with depressed mood (309.0) in accordance with DSM-III-R. The dosage was 3 x 300 mg hypericum extract LI 160 or 3 x 25 mg imipramine daily. The treatment lasted for 6 weeks. Main assessment criteria were the Hamilton Depression Scale (HAMD), the Depression Scale according to von Zerssen (D-S) and the Clinical Global Impressions (CGI). In both treatment groups, a parallel reduction of the Hamilton score from 20.2 to 8.8 (LI 160, n = 67) or from 19.4 to 10.7 (imipramine, n = 68), and the transformed D-S point values from 39.6 to 27.2 (LI 160) and 39.0 to 29.2 (imipramine) were found. The analysis of CGI revealed comparable results in both treatment groups. Clinically relevant changes of the safety parameters were not found. In the LI 160 group fewer and milder side effects were found as compared to imipramine.</abstract><cop>Los Angeles, CA</cop><pub>SAGE Publications</pub><pmid>7857502</pmid><doi>10.1177/089198879400701s07</doi><tpages>5</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0891-9887 |
| ispartof | Journal of geriatric psychiatry and neurology, 1994, Vol.7 (1_suppl), p.19-23 |
| issn | 0891-9887 1552-5708 |
| language | eng |
| recordid | cdi_crossref_primary_10_1177_089198879400701s07 |
| source | MEDLINE; SAGE Complete A-Z List |
| subjects | Adult Aged Antidepressive Agents - adverse effects Antidepressive Agents - therapeutic use Depression - diagnosis Depression - drug therapy Double-Blind Method Female Humans Hypericum Imipramine - adverse effects Imipramine - therapeutic use Male Middle Aged Perylene - adverse effects Perylene - analogs & derivatives Perylene - therapeutic use Plant Extracts - adverse effects Plant Extracts - therapeutic use Plants, Medicinal Psychometrics Quercetin - adverse effects Quercetin - analogs & derivatives Quercetin - therapeutic use Severity of Illness Index Xanthenes - adverse effects Xanthenes - therapeutic use |
| title | Effectiveness and Tolerance of the Hypericum Extract LI 160 in Comparison with Imipramine: Randomized Double-Blind Study with 135 Outpatients |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-20T14%3A04%3A30IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-sage_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Effectiveness%20and%20Tolerance%20of%20the%20Hypericum%20Extract%20LI%20160%20in%20Comparison%20with%20Imipramine:%20Randomized%20Double-Blind%20Study%20with%20135%20Outpatients&rft.jtitle=Journal%20of%20geriatric%20psychiatry%20and%20neurology&rft.au=Vorbach,%20E.-U.&rft.date=1994&rft.volume=7&rft.issue=1_suppl&rft.spage=19&rft.epage=23&rft.pages=19-23&rft.issn=0891-9887&rft.eissn=1552-5708&rft_id=info:doi/10.1177/089198879400701s07&rft_dat=%3Csage_cross%3E10.1177_089198879400701s07%3C/sage_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/7857502&rft_sage_id=10.1177_089198879400701s07&rfr_iscdi=true |